NASDAQ:CRDL Cardiol Therapeutics (CRDL) Stock Price, News & Analysis $1.12 -0.03 (-2.61%) Closing price 04:00 PM EasternExtended Trading$1.14 +0.02 (+2.23%) As of 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Cardiol Therapeutics Stock (NASDAQ:CRDL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cardiol Therapeutics alerts:Sign Up Key Stats Today's Range$1.12▼$1.1650-Day Range$0.99▼$1.5352-Week Range$0.77▼$2.63Volume626,310 shsAverage Volume384,395 shsMarket Capitalization$93.76 millionP/E RatioN/ADividend YieldN/APrice Target$8.00Consensus RatingBuy Company Overview Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada. Read More Cardiol Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScoreCRDL MarketRank™: Cardiol Therapeutics scored higher than 46% of companies evaluated by MarketBeat, and ranked 619th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingCardiol Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCardiol Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Cardiol Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cardiol Therapeutics are expected to grow in the coming year, from ($0.33) to ($0.30) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cardiol Therapeutics is -3.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cardiol Therapeutics is -3.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCardiol Therapeutics has a P/B Ratio of 11.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Cardiol Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.24% of the float of Cardiol Therapeutics has been sold short.Short Interest Ratio / Days to CoverCardiol Therapeutics has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Cardiol Therapeutics has recently increased by 2.33%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCardiol Therapeutics does not currently pay a dividend.Dividend GrowthCardiol Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.24% of the float of Cardiol Therapeutics has been sold short.Short Interest Ratio / Days to CoverCardiol Therapeutics has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Cardiol Therapeutics has recently increased by 2.33%, indicating that investor sentiment is decreasing. News and Social Media3.4 / 5News SentimentN/A News SentimentCardiol Therapeutics has a news sentiment score of 1.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.97 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Cardiol Therapeutics this week, compared to 1 article on an average week.Search Interest17 people have searched for CRDL on MarketBeat in the last 30 days. This is an increase of 113% compared to the previous 30 days.MarketBeat Follows15 people have added Cardiol Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 1,400% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cardiol Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.25% of the stock of Cardiol Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 12.49% of the stock of Cardiol Therapeutics is held by institutions.Read more about Cardiol Therapeutics' insider trading history. Receive CRDL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cardiol Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CRDL Stock News HeadlinesWhat is HC Wainwright's Estimate for CRDL FY2028 Earnings?August 20, 2025 | americanbankingnews.comCardiol Therapeutics Reports Q2 2025 Financial Results Amid Rising LossesAugust 14, 2025 | tipranks.comThis stock could leave NVDA in the dustInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla and Nvidia are all on the verge of major disruption. To help protect anyone with money invested in them, he's sharing three exciting stocks to replace them with. He gives away the names and tickers completely free in his brand-new "Sell This, Buy That" broadcast.August 27 at 2:00 AM | InvestorPlace (Ad)Cardiol Therapeutics Analyst RatingsJune 4, 2025 | benzinga.comCardiol Therapeutics Analyst RatingsJune 4, 2025 | benzinga.comHC Wainwright & Co. Initiates Coverage of Cardiol Therapeutics (CRDL) with Buy RecommendationJune 2, 2025 | msn.comCardiol Therapeutics Reports Q1 2025 Financial ResultsMay 27, 2025 | tipranks.comCardiol Therapeutics Reports Q1 2025 Financial ResultsMay 14, 2025 | tipranks.comSee More Headlines CRDL Stock Analysis - Frequently Asked Questions How have CRDL shares performed this year? Cardiol Therapeutics' stock was trading at $1.28 at the start of the year. Since then, CRDL shares have decreased by 12.5% and is now trading at $1.12. How were Cardiol Therapeutics' earnings last quarter? Cardiol Therapeutics Inc. (NASDAQ:CRDL) announced its quarterly earnings data on Thursday, August, 14th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.11) by $0.04. Who are Cardiol Therapeutics' major shareholders? Top institutional investors of Cardiol Therapeutics include Tejara Capital Ltd (3.95%), AdvisorShares Investments LLC (1.04%), MMCAP International Inc. SPC (0.35%) and Envestnet Asset Management Inc. (0.22%). How do I buy shares of Cardiol Therapeutics? Shares of CRDL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cardiol Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cardiol Therapeutics investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT (). Company Calendar Last Earnings8/14/2025Today8/27/2025Next Earnings (Estimated)11/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CRDL CIK1702123 Webwww.cardiolrx.com Phone(289) 910-0850FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Price Target for Cardiol Therapeutics$8.00 High Price Target$9.00 Low Price Target$7.00 Potential Upside/Downside+604.2%Consensus RatingBuy Rating Score (0-4)3.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$26.77 million Net MarginsN/A Pretax MarginN/A Return on Equity-232.26% Return on Assets-158.19% Debt Debt-to-Equity Ratio0.01 Current Ratio2.46 Quick Ratio2.46 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.10 per share Price / Book11.36Miscellaneous Outstanding Shares83,710,000Free Float79,317,000Market Cap$95.09 million OptionableNot Optionable Beta1.05 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:CRDL) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiol Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiol Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.